Condition

Esophageal Squamous Cell Carcinoma clinical trials and research

• 81Clinical trials
• 2NIH research projects
• 33Countries

Newest Esophageal Squamous Cell Carcinoma clinical trials

All recruiting trials (81)

• Radiotherapy target-volume choices in locally advanced esophageal cancer during immunotherapy

  This observational study looks at how doctors outline the radiation area for locally advanced esophageal squamous cell cancer patients treated with radiotherapy and immunotherapy to see which approaches correlate with better outcomes.

  Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Beijing Municipality · NCT07858630

• Sacituzumab Govitecan plus Tislelizumab for advanced esophageal cancer

  This phase II study tests whether the cancer-fighting drug sacituzumab tirumotecan (SKB264) combined with tislelizumab can help adults with advanced esophageal squamous cell carcinoma that progressed after initial immunotherapy.

  Recruiting at 2 sites Phase 2 Shanghai Chest Hospital · Shanghai and 1 other locations · NCT07811752

• Neoadjuvant therapy with adebrelimab, famitinib, and chemotherapy for resectable ESCC

  This study tests a combination of adebrelimab, famitinib, and chemotherapy before surgery in people with resectable locally advanced esophageal squamous cell carcinoma to see if it can lead to a complete tumor disappearance at the time of surgery.

  Recruiting Phase 2 First Affiliated Hospital Xi'an Jiaotong University · Xi'an, Shannxi · NCT07796113

• SKB500 combinations for esophageal squamous cell carcinoma

  This study tests SKB500 combined with other drugs to see if it is safe and shows early signs of activity in adults with unresectable or metastatic esophageal squamous cell carcinoma who have limited prior treatment.

  Recruiting at 24 sites Phase 2 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · Changchun and 23 other locations · NCT07700667

• Neoadjuvant Cardonilizumab With Chemotherapy Before Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma

  This study tests whether adding cardonilizumab to preoperative chemotherapy (versus chemoradiotherapy) helps patients with locally advanced ESCC have a better chance at complete tumor removal and longer survival.

  Recruiting Phase 2 Tongji Hospital · Wuhan, Hubei · NCT07699185

• Surgery or chemoradiotherapy after neoadjuvant immunochemotherapy for esophageal squamous cell carcinoma

  In people with locally advanced ESCC who respond to neoadjuvant immunochemotherapy, this study tests whether organ preservation with treatment other than surgery can be as effective as radical esophagectomy.

  Recruiting Phase 3 Henan Cancer Hospital · Zhengzhou, Henan · NCT07629817

• Tislelizumab plus chemotherapy for advanced gastric, gastroesophageal, and esophageal squamous cancers in U.S. racial and ethnic minority patients

  This will test whether adding tislelizumab to standard chemotherapy helps U.S. racial and ethnic minority patients with HER2-negative, PD-L1-positive unresectable or metastatic gastric, gastroesophageal, or esophageal squamous cell cancer.

  Recruiting at 9 sites Phase 2 BeOne Medicines · Bullhead City, Arizona and 8 other locations · NCT07554521

• BL-B01D1 with Tislelizumab ± 5-FU as first-line treatment for unresectable, locally advanced recurrent, or metastatic esophageal squamous cell carcinoma

  A phase II/III trial tests BL-B01D1 with tislelizumab, with or without 5-FU, against standard platinum-based chemotherapy plus tislelizumab for adults with unresectable or metastatic esophageal squamous cell carcinoma.

  Recruiting Phase 2/3 Sichuan Baili Pharmaceutical Co., Ltd. · Beijing, Beijing Municipality · NCT07554456

• Intensive nutrition during conversion therapy to enable surgery for locally advanced unresectable esophageal squamous cell carcinoma

  This will test whether giving intensive enteral nutrition alongside PD-1 inhibitor plus chemotherapy helps people with locally advanced unresectable esophageal squamous cell carcinoma achieve higher rates of complete tumor removal after conversion therapy.

  Recruiting Phase 2 Sichuan University · Chengdu, Sichuan · NCT07519486

• Camrelizumab, chemotherapy and Ivarmacitinib before surgery for resectable esophageal squamous cell carcinoma

  This trial tests whether giving camrelizumab with chemotherapy and the JAK inhibitor Ivarmacitinib before surgery can improve outcomes for patients with locally advanced esophageal squamous cell carcinoma that can be removed by operation.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, China · NCT07505186

• IDE034 for adults with advanced solid tumors that express B7-H3 and PTK7

  This trial will test IDE034 to see if it is safe and works in adults with advanced or metastatic solid tumors that express B7-H3 and PTK7.

  Recruiting at 26 sites Phase 1 IDEAYA Biosciences · Duarte, California and 25 other locations · NCT07503808

• Time-of-Day of Immunotherapy Infusion with Chemotherapy for Thoracic Esophageal Squamous Cell Carcinoma

  Researchers are testing if the time of day when the immunotherapy is given affects the success of treatment for resectable thoracic ESCC in combination with chemotherapy.

  Recruiting Phase 2 Tang-Du Hospital · Xi'an, Shannxi · NCT07452601

• Neoadjuvant adebrelimab plus chemotherapy for esophageal squamous cell carcinoma

  This study will test whether giving adebrelimab together with chemotherapy before surgery helps people with locally advanced esophageal squamous cell carcinoma.

  Recruiting Phase 2 The Affiliated Hospital of Putian University · Putian, Fujian · NCT07437898

• Vebrekotuzumab with or without anti-PD-1 for previously treated advanced esophageal squamous cell carcinoma

  This trial will test whether the EGFR-targeted antibody-drug conjugate vebrekotuzumab, alone or with an anti-PD-1 drug, helps people with advanced esophageal squamous cell carcinoma whose disease progressed after prior treatment.

  Recruiting Phase 2 Fudan University · Shanghai · NCT07403136

• Ivonescimab with albumin‑paclitaxel and cisplatin before surgery for esophageal squamous cell carcinoma

  This trial tests whether adding ivonescimab to albumin‑paclitaxel and cisplatin before surgery helps people with resectable, locally advanced esophageal squamous cell carcinoma.

  Recruiting Phase 1/2 Tang-Du Hospital · Xi'an, Shannxi · NCT07385001

• PLX-61639 for advanced SMARCA4-deficient solid tumors

  This trial will test a daily oral drug called PLX-61639 in people with advanced or metastatic solid tumors that have a SMARCA4 loss and who have no other approved treatment options.

  Recruiting at 10 sites Phase 1 Plexium, Inc. · Scottsdale, Arizona and 9 other locations · NCT07284186

• Envafolimab with albumin-bound paclitaxel and carboplatin before surgery for resectable locally advanced esophageal squamous cell carcinoma

  This study tests whether adding envafolimab to albumin-bound paclitaxel and carboplatin before surgery helps people with resectable locally advanced esophageal squamous cell carcinoma.

  Recruiting Phase 2 Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT07266493

• Ivonescimab plus chemotherapy before surgery for resectable esophageal squamous cell cancer

  This study tests whether giving Ivonescimab together with chemotherapy before esophageal cancer surgery helps patients see better outcomes than surgery alone.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07244978

• EVOLVE104 for advanced bladder and other squamous cell cancers

  This will try EVOLVE104, an experimental drug, in adults with advanced or metastatic bladder or other squamous cell cancers who have already tried or cannot take standard treatments.

  Recruiting at 16 sites Phase 1 EvolveImmune United, Inc · Duarte, California and 15 other locations · NCT07217171

• Ivonescimab with short-course hypofractionated radiotherapy for second-line esophageal squamous cell carcinoma

  This will try Ivonescimab plus a short course of higher‑dose radiotherapy as a second‑line option for adults (18–80) with locally advanced or metastatic esophageal squamous cell carcinoma who have failed first‑line therapy.

  Recruiting Phase 2 Anhui Provincial Hospital · Hefei, Anhui · NCT07188103

• Guided high‑dose‑rate esophageal brachytherapy with radiotherapy and nivolumab for esophageal squamous cell carcinoma

  We will test whether adding a guided high‑dose‑rate (HDR) esophageal brachytherapy session to prior radiotherapy, chemotherapy, and nivolumab helps people with locally advanced esophageal squamous cell carcinoma lower the chance the tumor returns near the esophagus within 12 months.

  Recruiting Phase 2 National Taiwan University Hospital · Huwei, Yunlin County · NCT07152678

• TER-2013 for advanced solid tumors with AKT/PI3K/PTEN pathway changes

  This trial tests whether TER-2013, alone or with fulvestrant, is safe and can help people with advanced breast, ovarian, endometrial, lung, or head-and-neck cancers that have AKT/PI3K/PTEN pathway alterations.

  Recruiting at 20 sites Phase 1/2 Terremoto Biosciences Inc. · Duarte, California and 24 other locations · NCT07109726

• PF-08046876 for people with advanced solid tumors

  This trial tests a new antibody–drug conjugate called PF-08046876 given by IV in adults with advanced bladder, lung, head and neck, esophageal, or pancreatic cancers to see if it is safe and how it affects tumors.

  Recruiting at 30 sites Phase 1 Pfizer · Duarte, California and 30 other locations · NCT07090499

• Using AI on CT scans to predict complete response in esophageal squamous cell carcinoma after neoadjuvant immunochemotherapy

  This project will test whether a deep-learning model using chest CT images and clinical data can predict which esophageal squamous cell carcinoma patients will have a complete pathological response after neoadjuvant immunochemotherapy.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT07088354

• Surufatinib with chemo-immunotherapy and chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma

  This trial will test whether adding surufatinib to two cycles of chemo-immunotherapy followed by concurrent chemoradiotherapy helps people with unresectable, locally advanced esophageal squamous cell carcinoma.

  Recruiting Phase 2 Sun Yat-sen University · Guangzhou, Guangdong · NCT07086469

• QL1706 plus celecoxib in advanced ESCC that progressed after prior immunotherapy

  This study tests whether giving QL1706 with celecoxib can help people with advanced esophageal squamous cell carcinoma who stopped responding to prior immune therapy.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing and 2 other locations · NCT07049185

• Neoadjuvant radiochemotherapy with cadonilizumab for locally advanced esophageal squamous cancer

  This phase 2 test adds cadonilizumab (a PD‑1/CTLA‑4 bi‑specific antibody) to standard neoadjuvant radiochemotherapy to see if it improves outcomes for people with locally advanced esophageal squamous cell carcinoma who are planned for surgery.

  Recruiting Phase 2 The First Affiliated Hospital of Zhengzhou University · Zhengzhou, Henan · NCT07016724

• Nimotuzumab combined with chemoradiotherapy for elderly patients with esophageal cancer

  This study is testing if adding a new drug called nimotuzumab to standard treatment helps older patients with advanced esophageal cancer feel better and live longer.

  Recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University · Nanjing · NCT06988956

• Skin tests to check biotherapy allergies in cancer patients

  We are testing skin tests to see if cancer patients treated with biotherapies have allergies or hypersensitivity to those drugs.

  Recruiting University Hospital, Angers · Angers · NCT06971848

• Combination therapies for esophageal squamous cell carcinoma (KEYMAKER-U06 Substudy 06E)

  This trial will test pembrolizumab together with an investigational antibody-drug conjugate (I-DXd), with or without chemotherapy, as a first-line treatment for people with locally advanced unresectable or metastatic esophageal squamous cell carcinoma.

  Recruiting at 52 sites Phase 1/2 Merck Sharp & Dohme LLC · Pittsburgh, Pennsylvania and 51 other locations · NCT06780111

• Investigating ALE.P02 for treating specific solid tumors in adults

  This study is testing a new treatment called ALE.P02 to see if it can safely help adults with advanced solid tumors that have a specific marker called Claudin-1.

  Recruiting at 39 sites Phase 1/2 Alentis Therapeutics AG · Scottsdale, Arizona and 40 other locations · NCT06747585

• Combining dalpiciclib and pyrotinib for advanced esophageal cancer treatment

  This study is testing if combining two drugs, dalpiciclib and pyrotinib, can help people with advanced esophageal cancer who haven't had success with their first treatment.

  Recruiting Phase 2 Peking University · Beijing, Beijing Municipality · NCT06684600

• Evaluating ifinatamab deruxtecan for advanced esophageal cancer

  This study is testing a new drug called ifinatamab deruxtecan to see if it helps people with advanced esophageal cancer who haven't responded to other treatments live longer and feel better compared to those getting standard chemotherapy.

  Recruiting at 167 sites Phase 3 Daiichi Sankyo · Phoenix, Arizona and 167 other locations · NCT06644781

• Combining benmelstobart with radiochemotherapy for esophageal cancer treatment

  This study is testing if adding a new drug called benmelstobart to standard radiation and chemotherapy can help people with esophageal cancer have better treatment outcomes before surgery.

  Recruiting at 5 sites Phase 2 Shanghai Zhongshan Hospital · Shantou, Guangdong and 4 other locations · NCT06637163

• Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy for esophageal cancer

  This study tests a new treatment plan that combines chemotherapy and immunotherapy before surgery, followed by more therapy after surgery, to see if it helps people with advanced esophageal cancer.

  Recruiting Anhui Provincial Hospital · Hefei · NCT06602843

• Neoadjuvant treatment strategies for advanced esophageal cancer

  This study is testing different treatment plans for patients with advanced esophageal cancer to see which one works best based on their CPS score.

  Recruiting Phase 2 Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT06601309

• Combining Adbelimumab with Chemotherapy and Apatinib for Esophageal Cancer Treatment

  This study is testing a new treatment that combines Adbelimumab with chemotherapy and Apatinib to see if it can help people with esophageal cancer live longer and reduce the chances of cancer coming back after surgery.

  Recruiting Phase 2 Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, China · NCT06576973

• Combining sintilimab with chemotherapy for treating esophageal cancer before surgery

  This study is testing if giving a new immunotherapy along with chemotherapy before surgery can help people with esophageal cancer have better outcomes.

  Recruiting Phase 3 The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT06563869

• Monitoring postoperative recurrence in esophageal cancer using ctDNA analysis

  This study is testing if tracking changes in tumor DNA after surgery can help predict if esophageal cancer will come back in patients who didn't fully respond to earlier treatment.

  Recruiting Sun Yat-sen University · Guangzhou, Guangdong · NCT06561178

• Treatment for advanced esophageal squamous cell carcinoma using adebrelimab and chemotherapy

  This study is testing if a new immunotherapy called adebrelimab, with or without chemotherapy, can help people with advanced esophageal cancer feel better and improve their treatment outcomes.

  Recruiting Phase 2 Fujian Medical University Union Hospital · Fuzhou, Fujian · NCT06510660

• Neoadjuvant treatment for esophageal squamous cell carcinoma

  This study is testing two different treatment plans for patients with operable esophageal squamous cell carcinoma to see which one works better and is safer before surgery.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06509568

• Predicting how well chemotherapy will work for esophageal cancer patients

  This study is testing if DNA changes in biopsy samples can help doctors predict how well chemotherapy will work for patients with esophageal cancer, so those who might not benefit can avoid unnecessary treatment.

  Recruiting City of Hope Medical Center · Chūō, Yamanashi · NCT06490003

• Combining Sintilimab with Chemotherapy for Esophageal Cancer Treatment

  This study is testing if combining a new drug called sintilimab with chemotherapy can help people with advanced esophageal cancer before surgery.

  Recruiting Phase 2 Fujian Cancer Hospital · Fuzhou, Fujian · NCT06463834

• Combining low-dose radiation with immunochemotherapy for esophageal cancer treatment

  This study is testing whether using low-dose radiation along with chemotherapy and immunotherapy can help improve treatment outcomes for patients with advanced esophageal cancer before surgery.

  Recruiting Phase 2 Sichuan University · Chengdu, Sichuan · NCT06446726

• Combining short-course radiotherapy with Raltitrexed and Tislelizumab for advanced esophageal cancer

  This study is testing a new treatment that combines short radiation therapy with two medications to see if it helps people with advanced esophageal cancer that has come back or gotten worse.

  Recruiting Anhui Provincial Hospital · Hefei · NCT06408584

• Neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma

  This study is testing two different treatment plans for people with advanced esophageal cancer to see which one works better and is safer before surgery.

  Recruiting Phase 2/3 Army Medical Center of PLA · Chongqing, None Selected · NCT06354530

• Combining Tislelizumab and S-1 for Esophageal Cancer Treatment

  This study is testing a new combination of two drugs, Tislelizumab and S-1, to see if it can help patients with esophageal cancer who have had surgery and still have some cancer left.

  Recruiting Phase 2 Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Chongqing, Chongqing Municipality · NCT06354140

• Using sacituzumab govitecan for advanced esophageal squamous cell carcinoma

  This study is testing a new treatment called sacituzumab govitecan for people with advanced esophageal squamous cell carcinoma whose previous treatments didn’t work, to see if it can help them.

  Recruiting Phase 2 National Taiwan University Hospital · Taipei · NCT06329869

• Comparing KC1036 to standard chemotherapy for advanced esophageal cancer

  This study is testing if a new treatment called KC1036 can work better than standard chemotherapy for people with advanced esophageal cancer.

  Recruiting Phase 3 Beijing Konruns Pharmaceutical Co., Ltd. · Beijing · NCT06194734

• Treatment for patients with oligometastatic esophageal cancer using PD-1 inhibitors and local therapy

  This study is testing if adding local treatments like surgery or radiation to a PD-1 inhibitor and chemotherapy can help people with oligometastatic esophageal cancer live longer without their cancer getting worse.

  Recruiting Phase 3 Fudan University · Shanghai · NCT06190782

• Using sintilimab after surgery for esophageal cancer

  This study tests if a medication called sintilimab can help prevent cancer from coming back in people who have had surgery for esophageal cancer.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hangzhou, Zhejiang · NCT06190639

• Combining immunotherapy with chemoradiotherapy for advanced esophageal cancer

  This study is testing a new treatment that combines immunotherapy with chemotherapy and radiation to see if it helps people with advanced esophageal cancer live longer and complete their treatment better.

  Recruiting Phase 1/2 Shanghai Chest Hospital · Shanghai · NCT06173986

• Assessing the effects of ABBV-400 on advanced solid tumors

  This study is testing a new drug called ABBV-400 to see if it can help adults with advanced solid tumors like liver, pancreatic, and triple negative breast cancer feel better and manage their disease.

  Recruiting at 47 sites Phase 1 AbbVie · Duarte, California and 53 other locations · NCT06084481

• Combining Tislelizumab with Chemotherapy for Esophageal Cancer Treatment

  This study is testing if combining a new immune therapy called tislelizumab with chemotherapy can help people with esophageal cancer live longer and stay cancer-free after surgery.

  Recruiting Phase 2 Shanghai Chest Hospital · Shanghai, Shanghai Municipality · NCT06056336

• Testing NEO212 for treating certain brain tumors and metastases

  This study is testing a new treatment called NEO212 for people with certain types of brain tumors to see if it is safe and effective when combined with standard treatments.

  Recruiting at 8 sites Phase 1/2 Neonc Technologies, Inc. · Beverly Hills, California and 7 other locations · NCT06047379

• Neoadjuvant therapy for resectable esophageal squamous cell carcinoma

  This study is testing if a new combination of treatments can help people with operable esophageal cancer do better than the usual chemotherapy before surgery.

  Recruiting at 3 sites Phase 2 Tang-Du Hospital · Xi'an, Shaanxi and 2 other locations · NCT06006650

• Combining chemotherapy with Tislelizumab for esophageal cancer after surgery

  This study is testing if combining an immunotherapy drug called Tislelizumab with chemotherapy can help people with esophageal cancer live longer after surgery.

  Recruiting Phase 1 Affiliated Cancer Hospital of Shantou University Medical College · Shantou, Guangdong · NCT05984342

• Combining radiotherapy with immunotherapy for advanced esophageal cancer

  This study is testing if adding low-dose and regular radiotherapy to standard immunotherapy and chemotherapy can help people with advanced esophageal cancer live longer without their disease getting worse.

  Recruiting at 2 sites Phase 2 Shanghai Chest Hospital · Shanghai and 1 other locations · NCT05978193

• Combining chemoradiation with Tislelizumab for advanced esophageal cancer treatment

  This study is testing if combining chemoradiation with Tislelizumab can help people with advanced esophageal cancer live longer without their disease getting worse.

  Recruiting Phase 3 Renmin Hospital of Wuhan University · Wuhan, Hubei · NCT05919030

• Combining immunonutrition with chemoradiotherapy for inoperable esophageal cancer

  This study is testing whether a special nutritional formula can help people with inoperable esophageal cancer live longer and feel better when combined with chemoradiotherapy.

  Recruiting Anhui Provincial Hospital · Hefei · NCT05833594

• Comparing two treatment approaches for esophageal squamous cell carcinoma

  This study is testing whether adding extra chemotherapy to standard treatment can help people with inoperable esophageal squamous cell carcinoma live longer and feel better.

  Recruiting The First Affiliated Hospital with Nanjing Medical University · Nanjing, Jiangsu · NCT05775419

• Neoadjuvant anti-PD-1 plus chemotherapy for esophageal cancer

  This study is testing if combining a new immune therapy with chemotherapy can help people with advanced esophageal cancer do better and live longer.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT05740995

• Evaluating Itraconazole for Treating Esophageal Cancer

  This study is testing if adding the antifungal medication itraconazole to standard treatment can help improve outcomes for patients with operable esophageal cancer.

  Recruiting at 7 sites Phase 2 VA Office of Research and Development · Palo Alto, California and 6 other locations · NCT05563766

• Neoadjuvant therapy with immunotherapy for esophageal cancer

  This study is testing a new treatment combining radiation, chemotherapy, and an immunotherapy drug to see if it helps people with esophageal cancer before surgery.

  Recruiting Phase 2 Zhejiang Cancer Hospital · Hanzhou, Zhejiang and 2 other locations · NCT05507411

• Using Sintilimab to treat advanced esophageal cancer after surgery

  This study is testing if the immunotherapy drug Sintilimab can help people with advanced esophageal cancer who are at high risk of their cancer coming back after surgery.

  Recruiting at 2 sites Phase 3 Henan Cancer Hospital · Zhengzhou, Henan and 1 other locations · NCT05495152

• Predicting the effectiveness of PD-1 monoclonal antibody treatment for advanced esophageal cancer

  This study is trying to see if changes in immune cells can help predict how well PD-1 antibody treatment works for people with advanced esophageal cancer.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou · NCT05392413

• Evaluating new treatments for advanced esophageal cancer after prior PD-1 therapy

  This study is testing new treatment combinations for people with advanced esophageal cancer who didn't respond to previous PD-1 therapy to see if they can improve their outcomes.

  Recruiting at 48 sites Phase 1/2 Merck Sharp & Dohme LLC · Tucson, Arizona and 57 other locations · NCT05319730

• Combination of Anlotinib and TQB2450 for Esophageal Cancer Treatment

  This study is testing if combining two medications, Anlotinib and TQB2450, can help people with esophageal cancer stay cancer-free after surgery.

  Recruiting Phase 2 Jiangxi Provincial Cancer Hospital · Nanchang, Jiangxi · NCT05252078

• Testing a new drug for advanced solid tumors

  This study is testing a new drug for people with advanced solid tumors, like lung and head and neck cancers, to see if it works better when combined with another treatment after other options have failed.

  Recruiting at 62 sites Phase 1 Seagen Inc. · Birmingham, Alabama and 61 other locations · NCT05208762

• RAPA-201 therapy for solid tumors

  This study is testing a new type of immune therapy using specially modified T cells from patients' own blood to see if it can help people with advanced solid tumors that haven't improved with other treatments.

  Recruiting Phase 1/2 Rapa Therapeutics LLC · Hackensack, New Jersey · NCT05144698

• New method for early detection of esophageal cancer

  This study is testing a new swallowable sponge device to see if it can help find esophageal cancer and its early signs in people at high risk.

  Recruiting at 2 sites University of California, San Francisco · Dar es Salaam, Mloganzila and 1 other locations · NCT05028725

• Combining pembrolizumab with chemotherapy for esophageal cancer treatment

  This study is testing if combining a drug called pembrolizumab with chemotherapy can help people with advanced esophageal cancer live longer and have better outcomes before surgery compared to standard treatment.

  Recruiting Phase 3 Tianjin Medical University Cancer Institute and Hospital · Tianjin, Tianjin Municipality · NCT04807673

• Evaluating blood lymphocyte changes in thoracic cancer patients undergoing treatment

  This study is trying to see how treatment affects blood cells in patients with lung cancer, esophageal cancer, or thymic tumors to understand their health better.

  Recruiting Shanghai Cancer Hospital, China · Shanghai, Shanghai Municipality · NCT04522687

• Treatment options for elderly patients with esophageal squamous cell carcinoma

  This study is testing whether combining chemotherapy with radiation helps older patients over 75 with advanced esophageal cancer live longer and feel better compared to just radiation alone.

  Recruiting at 3 sites Fudan University · Nanjing, Jiangsu and 2 other locations · NCT04519905

• Collection of tumor samples from cancer patients for diagnostic test development

  This study is collecting tumor samples from cancer patients who are getting certain treatments to help create better tests for managing cancer in the future.

  Recruiting Cofactor Genomics, Inc. · San Francisco, California · NCT04510129

• Comparing two treatment approaches for esophageal cancer

  This study is testing two different treatment plans for people with advanced esophageal cancer to see which one helps them live longer and feel better after a year.

  Recruiting at 12 sites Phase 3 Karolinska University Hospital · Montreal, Quebec and 11 other locations · NCT04460352

• Testing a new drug for advanced solid tumors

  This study is testing a new drug called sigvotatug vedotin to see if it can safely help people with advanced solid tumors, both on its own and with other treatments.

  Recruiting at 145 sites Phase 1 Seagen Inc. · Anchorage, Alaska and 157 other locations · NCT04389632

• Evaluating the effects of prophylactic irradiation in esophageal cancer treatment

  This study tests if a new treatment combining chemotherapy and radiation can help people with esophageal cancer avoid the cancer coming back while keeping their esophagus and improving survival.

  Recruiting Phase 3 National Cancer Center, Japan · Tokyo · NCT04328948

• Registry for gastric and esophageal cancer treatments in Germany

  This study is collecting information on how patients in Germany with advanced esophageal and stomach cancers are treated to see how well different treatments work in real life.

  Recruiting iOMEDICO AG · Multiple Locations · NCT04290806

• Comparing chemotherapy and chemoradiotherapy before surgery for esophageal cancer

  This study is testing whether giving patients with esophageal cancer chemotherapy or a combination of chemotherapy and radiation before surgery helps them live longer.

  Recruiting Phase 3 Henan Cancer Hospital · Zhengzhou, Henan · NCT04138212

• Combination of nab-paclitaxel and cisplatin before surgery for esophageal cancer

  This study is testing if a combination of nab-paclitaxel and cisplatin before surgery can help people with advanced esophageal cancer have better outcomes compared to just having surgery alone.

  Recruiting Phase 2 Hebei Medical University Fourth Hospital · Shijiazhuang, Hebei · NCT03964753

NIH-funded research (2)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Understanding and treating a specific type of esophageal cancer with high NRF2 levels

  This study is looking at a specific type of esophageal cancer that has high levels of a protein called NRF2, which might help the cancer grow, and the researchers want to find ways to block this protein to create better treatments for patients.

  NIH research Coriell Institute for Medical Research · Camden, United States · NIH-11006288

• A new test for early detection of esophageal cancer using a swallowable capsule.

  This study is working on a simple and affordable test that uses a swallowable sponge to check for early signs of esophageal cancer, making it easier for people in the U.S. and Uganda to get diagnosed and treated sooner.

  NIH research Capsulomics, LLC · Baltimore, UNITED STATES · NIH-10921933

Related topics

Quick answers

How many Esophageal Squamous Cell Carcinoma clinical trials are recruiting right now?

81, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 33 countries. The most sites are in China (61 trials), United States (17 trials), Taiwan (9 trials), Spain (8 trials), Japan (7 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 36, Phase 3: 11, Phase 1: 8, Phase 1/2: 8. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →